共 88 条
[1]
Bullingham R(1996)Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration J Clin Pharmacol 36 315-324
[2]
Monroe S(2015)Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil Eur J Clin Pharmacol 71 95-106
[3]
Nicholls A(1990)Bioavailability improvement of mycophenolic acid through amino ester derivatization Pharm Res 7 161-166
[4]
Ling J(2005)Enteric-coated mycophenolate sodium for transplant immunosuppression Am J Health Syst Pharm 62 2252-2259
[5]
Shi J(2012)Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing Transplant Rev (Orlando) 26 233-240
[6]
Jiang Q(1996)Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients Transplantation 62 666-672
[7]
Lee WA(1996)Pharmacokinetics of mycophenolate mofetil (RS61443): a short review Transplant Proc 28 925-929
[8]
Gu L(1998)The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation Clin Pharmacol Ther 64 672-683
[9]
Miksztal AR(1999)A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 261-266
[10]
Ingle GR(1999)Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil Br J Pharmacol 126 1075-1082